| Comprehensive analysis of the clinical immuno-oncology landscape J Tang, A Shalabi, VM Hubbard-Lucey Annals of Oncology 29 (1), 84-91, 2018 | 513 | 2018 |
| A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation R Duivenvoorden, J Tang, DP Cormode, AJ Mieszawska, ... Nature communications 5 (1), 3065, 2014 | 450 | 2014 |
| Immunotherapy and targeted therapy combinations in metastatic breast cancer FJ Esteva, VM Hubbard-Lucey, J Tang, L Pusztai The lancet oncology 20 (3), e175-e186, 2019 | 405 | 2019 |
| The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors J Tang, JX Yu, VM Hubbard-Lucey, N Svetoslav T, H Jeffrey P, Y Lin Nature Reviews Drug Discovery 17, 854-855, 2018 | 356* | 2018 |
| Immuno-oncology drug development goes global JX Yu, VM Hubbard-Lucey, J Tang Nat Rev Drug Discov 18 (12), 899-900, 2019 | 236 | 2019 |
| Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation J Tang, ME Lobatto, L Hassing, S van der Staay, SM van Rijs, C Calcagno, ... Science Advances 1 (3), e1400223, 2015 | 223 | 2015 |
| Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer A Gianella, PA Jarzyna, V Mani, S Ramachandran, C Calcagno, J Tang, ... ACS nano 5 (6), 4422-4433, 2011 | 200 | 2011 |
| Trends in clinical development for PD-1/PD-L1 inhibitors [J] N Durvalumab Nature reviews| Drug Discovery 19, 163, 2020 | 192 | 2020 |
| PET Imaging of Tumor-Associated Macrophages with 89Zr-labeled HDL Nanoparticles. C Perez-Medina, J Tang, D Abdel-Atti, B Hogstad, M Merad, EA Fisher, ... The Journal of Nuclear Medicine, 2015 | 175 | 2015 |
| Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis TJ Beldman, ML Senders, A Alaarg, C Pérez-Medina, J Tang, Y Zhao, ... Acs Nano 11 (6), 5785-5799, 2017 | 163 | 2017 |
| Trends in the global immuno-oncology landscape J Tang, L Pearce, J O’Donnell-Tormey, VM Hubbard-Lucey Nature Reviews Drug Discovery 130 (176), 112, 2018 | 156 | 2018 |
| Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis TTP Seijkens, CM van Tiel, PJH Kusters, D Atzler, O Soehnlein, ... Journal of the American College of Cardiology 71 (5), 527-542, 2018 | 156 | 2018 |
| HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages BL Sanchez-Gaytan, F Fay, ME Lobatto, J Tang, M Ouimet, YT Kim, ... Bioconjugate chemistry 26 (3), 443-451, 2015 | 151 | 2015 |
| Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics YT Kim, F Fay, DP Cormode, BL Sanchez-Gaytan, J Tang, EJ Hennessy, ... ACS nano 7 (11), 9975-9983, 2013 | 126 | 2013 |
| Immune cell screening of a nanoparticle library improves atherosclerosis therapy J Tang, S Baxter, A Menon, A Alaarg, BL Sanchez-Gaytan, F Fay, Y Zhao, ... Proceedings of the National Academy of Sciences 113 (44), E6731-E6740, 2016 | 114 | 2016 |
| Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease MA Lameijer, J Tang, M Nahrendorf, RHJ Beelen, WJM Mulder Expert review of molecular diagnostics 13 (6), 567-580, 2013 | 114 | 2013 |
| Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy C Pérez-Medina, D Abdel-Atti, J Tang, Y Zhao, ZA Fayad, JS Lewis, ... Nature communications 7 (1), 11838, 2016 | 111 | 2016 |
| Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates M Lameijer, T Binderup, MMT Van Leent, ML Senders, F Fay, J Malkus, ... Nature biomedical engineering 2 (5), 279-292, 2018 | 107 | 2018 |
| The Global Pipeline of Cell Therapies for Cancer JT Jia Xin Yu, Vanessa M. Hubbard-Lucey Nature Reviews Drug Discovery, 2019 | 103 | 2019 |
| In vivo PET imaging of HDL in multiple atherosclerosis models C Pérez-Medina, T Binderup, ME Lobatto, J Tang, C Calcagno, L Giesen, ... JACC: Cardiovascular Imaging 9 (8), 950-961, 2016 | 102 | 2016 |
Willem J. M. MulderRadboud University Medical CenterVerified email at radboudumc.nl
